Clinical activity of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC) and a BRCA mutation (BRCAmut): Analysis of pooled data from Study 10 (parts 1, 2a, and 3) and ARIEL2 (parts 1 and 2) Meeting Abstract
| Authors: | Kristeleit, R. S.; Shapira-Frommer, R.; Oaknin, A.; Balmana, J.; Ray-Coquard, I. L.; Domchek, S.; Tinker, A. V.; Castro, C. M.; Welch, S.; Poveda, A. M.; Bell-Mcguinn, K.; Konecny, G.; Giordano, H.; Maloney, L.; Goble, S.; Rolfe, L.; Oza, A. |
| Abstract Title: | Clinical activity of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC) and a BRCA mutation (BRCAmut): Analysis of pooled data from Study 10 (parts 1, 2a, and 3) and ARIEL2 (parts 1 and 2) |
| Meeting Title: | 41st European Society for Medical Oncology Congress (ESMO) |
| Journal Title: | Annals of Oncology |
| Volume: | 27 |
| Issue: | Suppl. 6 |
| Meeting Dates: | 2016 Oct 7-11 |
| Meeting Location: | Copenhagen, Denmark |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2016-10-01 |
| Start Page: | vi296 |
| Language: | English |
| ACCESSION: | WOS:000393912500851 |
| DOI: | 10.1093/annonc/mdw374.03 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 856O -- Source: Wos |
